Meeting
2018 Genitourinary Cancers Symposium
Plasma miR371 for the detection of viable germ cell tumor in testicular cancer patients with enlarging or post chemotherapy residual nodes.
Authors
Lucia Nappi
Vancouver Prostate Centre and SWOG AYA, Prevention and Surveillance and SWOG YI Award, Vancouver, BC, Canada
Lucia Nappi , Marisa Thi , Bernhard J. Eigl , Kim N. Chi , Martin Gleave , Alan I. So , Daniel Khalaf , Peter C. Black , Craig R. Nichols , Christian K. Kollmannsberger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Penile, Urethral, and Testicular Cancers
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 569)
DOI
10.1200/JCO.2018.36.6_suppl.569
Abstract #
569
Poster Bd #
M6
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Circulating miR-371a-3p for the detection of low volume viable germ cell tumor: Expanded pilot data, clinical implications and future study.
First Author: Lucia Nappi
Poster
2024 ASCO Annual Meeting
Management of relapsed stage I nonseminomatous germ-cell tumor with retroperitoneal only relapse.
First Author: Ahmed Bilal Khalid
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase II trial evaluating the efficacy of cabozantinib in the treatment of patients with refractory germ-cell tumors (GCT).
First Author: Jennifer King
Poster
2020 ASCO Virtual Scientific Program
Olaparib as salvage treatment for advanced germ cell tumors after chemotherapy failure: Results of the open-label, single-arm, IGG-02 phase II trial.
First Author: Ugo De Giorgi